Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2013

Open Access 01-12-2013 | Review

Cardiac implications of hypoglycaemia in patients with diabetes – a systematic review

Authors: Markolf Hanefeld, Eva Duetting, Peter Bramlage

Published in: Cardiovascular Diabetology | Issue 1/2013

Login to get access

Abstract

Background

Hypoglycaemia has been associated with increased cardiovascular (CV) risk and mortality in a number of recent multicentre trials, but the mechanistic links driving this association remain ill defined. This review aims to summarize the available data on how hypoglycaemia may affect CV risk in patients with diabetes.

Methods

This was a systematic review of available mechanistic and clinical studies on the relationship between hypoglycaemia and cardiovascular risk. Study outcomes were compiled from relevant articles, and factors contributing to hypoglycaemia-mediated CVD and its complications are discussed.

Results

Six recent comprehensive clinical trials have reinforced the critical importance of understanding the link between hypoglycaemia and the CV system. In addition, 88 studies have indicated that hypoglycaemia mechanistically contributes to CV risk by increasing thrombotic tendency, causing abnormal cardiac repolarization, inducing inflammation, and contributing to the development of atherosclerosis. These hypoglycaemia-associated risk factors are conducive to events such as unstable angina, non-fatal and fatal myocardial infarction, sudden death, and stroke in patients with diabetes.

Conclusions

Emerging data suggest that there is an impact of hypoglycaemia on CV function and mechanistic link is multifactorial. Further research will be needed to ascertain the full impact of hypoglycaemia on the CV system and its complications.
Appendix
Available only for authorised users
Literature
1.
Tu E, Twigg SM, Duflou J, Semsarian C: Causes of death in young Australians with type 1 diabetes: a review of coronial postmortem examinations. Med J Aust. 2008, 188 (12): 699-702.PubMed
2.
Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H: Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia. 2001, 44 (Suppl 2): S14-21.CrossRefPubMed
3.
Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, Gatling W, Bingley PJ, Patterson CC: Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia. 2003, 46 (6): 760-765. 10.1007/s00125-003-1116-6.CrossRefPubMed
4.
Wei M, Gibbons LW, Mitchell TL, Kampert JB, Stern MP, Blair SN: Low fasting plasma glucose level as a predictor of cardiovascular disease and all-cause mortality. Circulation. 2000, 101 (17): 2047-2052. 10.1161/01.CIR.101.17.2047.CrossRefPubMed
5.
Johnston SS, Conner C, Aagren M, Smith DM, Bouchard J, Brett J: Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care. 2011, 34 (5): 1164-1170. 10.2337/dc10-1915.PubMedCentralCrossRefPubMed
6.
Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neal B, MacMahon S, Grobbee DE, Kengne AP, Marre M, Heller S: Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010, 363 (15): 1410-1418. 10.1056/NEJMoa1003795.CrossRefPubMed
7.
UK Hypoglycaemia Study Group: Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007, 50 (6): 1140-1147.CrossRef
8.
Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Probstfield JL, Simons-Morton DG, Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008, 358 (24): 2545-2559.CrossRefPubMed
9.
Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008, 358 (24): 2560-2572.CrossRefPubMed
10.
Moritz T, Duckworth W, Abraira C: Veterans affairs diabetes trial–corrections. N Engl J Med. 2009, 361 (10): 1024-1025.CrossRefPubMed
11.
Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm RH, Byington RP, Rosenberg YD, Friedewald WT: Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011, 364 (9): 818-828.CrossRefPubMed
12.
Dandona P, Chaudhuri A, Dhindsa S: Proinflammatory and prothrombotic effects of hypoglycemia. Diabetes Care. 2010, 33 (7): 1686-1687. 10.2337/dc10-0503.PubMedCentralCrossRefPubMed
13.
Robinson RT, Harris ND, Ireland RH, Lee S, Newman C, Heller SR: Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycemia. Diabetes. 2003, 52 (6): 1469-1474. 10.2337/diabetes.52.6.1469.CrossRefPubMed
14.
Wright RJ, Newby DE, Stirling D, Ludlam CA, Macdonald IA, Frier BM: Effects of acute insulin-induced hypoglycemia on indices of inflammation: putative mechanism for aggravating vascular disease in diabetes. Diabetes Care. 2010, 33 (7): 1591-1597. 10.2337/dc10-0013.PubMedCentralCrossRefPubMed
15.
Dave KR, Tamariz J, Desai KM, Brand FJ, Liu A, Saul I, Bhattacharya SK, Pileggi A: Recurrent hypoglycemia exacerbates cerebral ischemic damage in streptozotocin-induced diabetic rats. Stroke. 2011, 42 (5): 1404-1411. 10.1161/STROKEAHA.110.594937.CrossRefPubMed
16.
Gimenez M, Gilabert R, Monteagudo J, Alonso A, Casamitjana R, Pare C, Conget I: Repeated episodes of hypoglycemia as a potential aggravating factor for preclinical atherosclerosis in subjects with type 1 diabetes. Diabetes Care. 2011, 34 (1): 198-203. 10.2337/dc10-1371.PubMedCentralCrossRefPubMed
17.
Tanenberg RJ, Newton CA, Drake AJ: Confirmation of hypoglycemia in the “dead-in-bed” syndrome, as captured by a retrospective continuous glucose monitoring system. Endocr Pract. 2010, 16 (2): 244-248. 10.4158/EP09260.CR.CrossRefPubMed
18.
McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA: Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care. 2012, 35 (9): 1897-1901. 10.2337/dc11-2054.PubMedCentralCrossRefPubMed
19.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009, 339: b2700-10.1136/bmj.b2700.PubMedCentralCrossRefPubMed
20.
21.
Swinnen SG, Mullins P, Miller M, Hoekstra JB, Holleman F: Changing the glucose cut-off values that define hypoglycaemia has a major effect on reported frequencies of hypoglycaemia. Diabetologia. 2009, 52 (1): 38-41. 10.1007/s00125-008-1147-0.CrossRefPubMed
22.
American Diabetes Association Workgroup on Hypoglycemia: Defining and reporting hypoglycemia in diabetes: a report from the American diabetes association workgroup on hypoglycemia. Diabetes Care. 2005, 28 (5): 1245-1249.CrossRef
23.
Bay C, Kristensen PL, Pedersen-Bjergaard U, Tarnow L, Thorsteinsson B: Nocturnal continuous glucose monitoring: accuracy and reliability of hypoglycemia detection in patients with type 1 diabetes at high risk of severe hypoglycemia. Diabetes Technol Ther. 2013, 15 (5): 371-377. 10.1089/dia.2013.0004.CrossRefPubMed
24.
Gerich JE, Langlois M, Noacco C, Karam JH, Forsham PH: Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect. Science. 1973, 182 (4108): 171-173. 10.1126/science.182.4108.171.CrossRefPubMed
25.
Graveling AJ, Frier BM: Impaired awareness of hypoglycaemia: a review. Diabetes Metab. 2010, 36 (Suppl 3): S64-74.CrossRefPubMed
26.
Gold AE, MacLeod KM, Frier BM: Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care. 1994, 17 (7): 697-703. 10.2337/diacare.17.7.697.CrossRefPubMed
27.
Jauch-Chara K, Schultes B: Sleep and the response to hypoglycaemia. Best Pract Res Clin Endocrinol Metab. 2010, 24 (5): 801-815. 10.1016/j.beem.2010.07.006.CrossRefPubMed
28.
29.
Jacobson AM, Musen G, Ryan CM, Silvers N, Cleary P, Waberski B, Burwood A, Weinger K, Bayless M, Dahms W, Harth J: Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med. 2007, 356 (18): 1842-1852.CrossRefPubMed
30.
Skrivarhaug T, Bangstad HJ, Stene LC, Sandvik L, Hanssen KF, Joner G: Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. Diabetologia. 2006, 49 (2): 298-305. 10.1007/s00125-005-0082-6.CrossRefPubMed
31.
Tschope D, Bramlage P, Binz C, Krekler M, Deeg E, Gitt AK: Incidence and predictors of hypoglycaemia in type 2 diabetes – an analysis of the prospective DiaRegis registry. BMC Endocr Disord. 2012, 12 (1): 23-10.1186/1472-6823-12-23.PubMedCentralCrossRefPubMed
32.
Tschope D, Bramlage P, Binz C, Krekler M, Plate T, Deeg E, Gitt AK: Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients–an analysis of the DiaRegis registry. Cardiovasc Diabetol. 2011, 10: 66-10.1186/1475-2840-10-66.PubMedCentralCrossRefPubMed
33.
Bramlage P, Binz C, Gitt AK, Krekler M, Plate T, Deeg E, Tschope D: Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis) - study protocol and patient characteristics at baseline. Cardiovasc Diabetol. 2010, 9: 53-10.1186/1475-2840-9-53.PubMedCentralCrossRefPubMed
34.
Gitt AK, Bramlage P, Binz C, Krekler M, Deeg E, Tschope D: Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry. Int J Clin Pract. 2013, doi:10.1111/ijcp.12179 [Epub ahead of print]
35.
Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant R, Band MM, Reekie G, Leese GP: Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population-based study. Diabet Med. 2005, 22 (6): 749-755. 10.1111/j.1464-5491.2005.01501.x.CrossRefPubMed
36.
Bramlage P, Gitt AK, Binz C, Krekler M, Deeg E, Tschope D: Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia. Cardiovasc Diabetol. 2012, 11: 122-10.1186/1475-2840-11-122.PubMedCentralCrossRefPubMed
37.
38.
Snell-Bergeon JK, Wadwa RP: Hypoglycemia, diabetes, and cardiovascular disease. Diabetes Technol Ther. 2012, 14 (Suppl 1): S51-58.PubMed
39.
The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the diabetes control and complications trial research group. N Engl J Med. 1993, 329 (14): 977-986.CrossRef
40.
de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B: Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med. 2011, 365 (25): 2366-2376.CrossRefPubMed
41.
UK prospective diabetes study (UKPDS) group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) group. Lancet. 1998, 352 (9131): 837-853.CrossRef
42.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008, 359 (15): 1577-1589. 10.1056/NEJMoa0806470.CrossRefPubMed
43.
Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, Dudl RJ, Ismail-Beigi F, Kimel AR, Hoogwerf B, Horowitz KR, Savage PJ, Seaquist ER, Simmons DL, Sivitz WI, Speril-Hillen JM, Sweeney ME: The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010, 340: b4909-10.1136/bmj.b4909.PubMedCentralCrossRefPubMed
44.
Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, Goff DC, Malozowski S, Margolis KL, Probstfield JL, Schnall A, Seaquist ER: Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care. 2010, 33 (5): 983-990. 10.2337/dc09-1278.PubMedCentralCrossRefPubMed
45.
Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009, 360 (2): 129-139. 10.1056/NEJMoa0808431.CrossRefPubMed
46.
Duckworth WC, Abraira C, Moritz TE, Davis SN, Emanuele N, Goldman S, Hayward R, Huang GD, Marks JB, Reaven PD, Reda DJ, Warren SR, Zieve FJ: The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA diabetes trial. J Diabetes Complications. 2011, 25 (6): 355-361. 10.1016/j.jdiacomp.2011.10.003.CrossRefPubMed
47.
Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Ryden LE, Yusuf S, ORIGIN Trials Investigators: Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012, 367 (4): 319-328.CrossRefPubMed
48.
Gogitidze Joy N, Hedrington MS, Briscoe VJ, Tate DB, Ertl AC, Davis SN: Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals. Diabetes Care. 2010, 33 (7): 1529-1535. 10.2337/dc09-0354.PubMedCentralCrossRefPubMed
49.
Dalsgaard-Nielsen J, Madsbad S, Hilsted J: Changes in platelet function, blood coagulation and fibrinolysis during insulin-induced hypoglycaemia in juvenile diabetics and normal subjects. Thromb Haemost. 1982, 47 (3): 254-258.PubMed
50.
Amiel SA, Sherwin RS, Simonson DC, Tamborlane WV: Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release. Diabetes. 1988, 37 (7): 901-907. 10.2337/diab.37.7.901.CrossRefPubMed
51.
Schwartz NS, Clutter WE, Shah SD, Cryer PE: Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest. 1987, 79 (3): 777-781. 10.1172/JCI112884.PubMedCentralCrossRefPubMed
52.
Petersen KG, Schluter KJ, Kerp L: Regulation of serum potassium during insulin-induced hypoglycemia. Diabetes. 1982, 31 (7): 615-617. 10.2337/diab.31.7.615.CrossRefPubMed
53.
Koivikko ML, Karsikas M, Salmela PI, Tapanainen JS, Ruokonen A, Seppanen T, Huikuri HV, Perkiomaki JS: Effects of controlled hypoglycaemia on cardiac repolarisation in patients with type 1 diabetes. Diabetologia. 2008, 51 (3): 426-435. 10.1007/s00125-007-0902-y.CrossRefPubMed
54.
Gill GV, Woodward A, Casson IF, Weston PJ: Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes–the ‘dead in bed’ syndrome revisited. Diabetologia. 2009, 52 (1): 42-45. 10.1007/s00125-008-1177-7.CrossRefPubMed
55.
Marques JL, George E, Peacey SR, Harris ND, Macdonald IA, Cochrane T, Heller SR: Altered ventricular repolarization during hypoglycaemia in patients with diabetes. Diabet Med. 1997, 14 (8): 648-654. 10.1002/(SICI)1096-9136(199708)14:8<648::AID-DIA418>3.0.CO;2-1.CrossRefPubMed
56.
Robinson RT, Harris ND, Ireland RH, Macdonald IA, Heller SR: Changes in cardiac repolarization during clinical episodes of nocturnal hypoglycaemia in adults with type 1 diabetes. Diabetologia. 2004, 47 (2): 312-315. 10.1007/s00125-003-1292-4.CrossRefPubMed
57.
Ceriello A, Novials A, Ortega E, La Sala L, Pujadas G, Testa R, Bonfigli AR, Esposito K, Giugliano D: Evidence that hyperglycemia after recovery from hypoglycemia worsens endothelial function and increases oxidative stress and inflammation in healthy control subjects and subjects with type 1 diabetes. Diabetes. 2012, 61 (11): 2993-2997. 10.2337/db12-0224.PubMedCentralCrossRefPubMed
58.
Dotson S, Freeman R, Failing HJ, Adler GK: Hypoglycemia increases serum interleukin-6 levels in healthy men and women. Diabetes Care. 2008, 31 (6): 1222-1223. 10.2337/dc07-2243.CrossRefPubMed
59.
Razavi Nematollahi L, Kitabchi AE, Stentz FB, Wan JY, Larijani BA, Tehrani MM, Gozashti MH, Omidfar K, Taheri E: Proinflammatory cytokines in response to insulin-induced hypoglycemic stress in healthy subjects. Metabolism. 2009, 58 (4): 443-448. 10.1016/j.metabol.2008.10.018.CrossRefPubMed
60.
Gruden G, Barutta F, Chaturvedi N, Schalkwijk C, Stehouwer CD, Pinach S, Manzo M, Loiacono M, Tricarico M, Mengozzi G, Witte DR, Fuller JH, Perin PC, Bruno G: NH2-Terminal probrain natriuretic peptide is associated with diabetes complications in the EURODIAB prospective complications study: the role of tumor necrosis factor-alpha. Diabetes Care. 2012, 35 (9): 1931-1936. 10.2337/dc12-0089.PubMedCentralCrossRefPubMed
61.
Adler GK, Bonyhay I, Curren V, Waring E, Freeman R: Hypoglycaemia increases aldosterone in a dose-dependent fashion. Diabet Med. 2010, 27 (11): 1250-1255. 10.1111/j.1464-5491.2010.03087.x.PubMedCentralCrossRefPubMed
62.
Wright RJ, Frier BM: Vascular disease and diabetes: is hypoglycaemia an aggravating factor?. Diabetes Metab Res Rev. 2008, 24 (5): 353-363. 10.1002/dmrr.865.CrossRefPubMed
63.
Heller SR, Robinson RT: Hypoglycaemia and associated hypokalaemia in diabetes: mechanisms, clinical implications and prevention. Diabetes Obes Metab. 2000, 2 (2): 75-82. 10.1046/j.1463-1326.2000.00050.x.CrossRefPubMed
64.
Hutton RA, Mikhailidis D, Dormandy KM, Ginsburg J: Platelet aggregation studies during transient hypoglycaemia: a potential method for evaluating platelet function. J Clin Pathol. 1979, 32 (5): 434-438. 10.1136/jcp.32.5.434.PubMedCentralCrossRefPubMed
65.
Pfister R, Cairns R, Erdmann E, Schneider CA, Investigators PR: Prognostic impact of electrocardiographic signs in patients with type 2 diabetes and cardiovascular disease: results from the PROactive study. Diabet Med. 2011, 28 (10): 1206-1212. 10.1111/j.1464-5491.2011.03281.x.CrossRefPubMed
66.
Chelliah YR: Ventricular arrhythmias associated with hypoglycaemia. Anaesth Intensive Care. 2000, 28 (6): 698-700.PubMed
67.
Collier A, Matthews DM, Young RJ, Clarke BF: Transient atrial fibrillation precipitated by hypoglycaemia: two case reports. Postgrad Med J. 1987, 63 (744): 895-897. 10.1136/pgmj.63.744.895.PubMedCentralCrossRefPubMed
68.
DeRosa MA, Cryer PE: Hypoglycemia and the sympathoadrenal system: neurogenic symptoms are largely the result of sympathetic neural, rather than adrenomedullary, activation. Am J Physiol Endocrinol Metab. 2004, 287 (1): E32-41. 10.1152/ajpendo.00539.2003.CrossRefPubMed
69.
Koivikko ML, Salmela PI, Airaksinen KE, Tapanainen JS, Ruokonen A, Makikallio TH, Huikuri HV: Effects of sustained insulin-induced hypoglycemia on cardiovascular autonomic regulation in type 1 diabetes. Diabetes. 2005, 54 (3): 744-750. 10.2337/diabetes.54.3.744.CrossRefPubMed
70.
Kamijo Y, Soma K, Aoyama N, Fukuda M, Ohwada T: Myocardial infarction with acute insulin poisoning–a case report. Angiology. 2000, 51 (8): 689-693.PubMed
71.
Lindstrom T, Jorfeldt L, Tegler L, Arnqvist HJ: Hypoglycaemia and cardiac arrhythmias in patients with type 2 diabetes mellitus. Diabet Med. 1992, 9 (6): 536-541. 10.1111/j.1464-5491.1992.tb01834.x.CrossRefPubMed
72.
Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V: Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care. 2003, 26 (5): 1485-1489. 10.2337/diacare.26.5.1485.CrossRefPubMed
73.
Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Cavallo Perin P, Bruno G: QTc interval prolongation is independently associated with severe hypoglycemic attacks in type 1 diabetes from the EURODIAB IDDM complications study. Diabetes Care. 2012, 35 (1): 125-127. 10.2337/dc11-1739.PubMedCentralCrossRefPubMed
74.
Giunti S, Gruden G, Fornengo P, Barutta F, Amione C, Ghezzo G, Cavallo-Perin P, Bruno G: Increased QT interval dispersion predicts 15-year cardiovascular mortality in type 2 diabetic subjects: the population-based casale monferrato study. Diabetes Care. 2012, 35 (3): 581-583. 10.2337/dc11-1397.PubMedCentralCrossRefPubMed
75.
Christensen TF, Tarnow L, Randlov J, Kristensen LE, Struijk JJ, Eldrup E, Hejlesen OK: QT interval prolongation during spontaneous episodes of hypoglycaemia in type 1 diabetes: the impact of heart rate correction. Diabetologia. 2010, 53 (9): 2036-2041. 10.1007/s00125-010-1802-0.CrossRefPubMed
76.
The DCCT research group: Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT research group. Am J Med. 1991, 90 (4): 450-459.CrossRef
77.
Murphy NP, Ford-Adams ME, Ong KK, Harris ND, Keane SM, Davies C, Ireland RH, MacDonald IA, Knight EJ, Edge JA, Heller SR, Dunger DB: Prolonged cardiac repolarisation during spontaneous nocturnal hypoglycaemia in children and adolescents with type 1 diabetes. Diabetologia. 2004, 47 (11): 1940-1947. 10.1007/s00125-004-1552-y.CrossRefPubMed
78.
Tattersall RB, Gill GV: Unexplained deaths of type 1 diabetic patients. Diabet Med. 1991, 8 (1): 49-58. 10.1111/j.1464-5491.1991.tb01516.x.CrossRefPubMed
79.
Thordarson H, Sovik O: Dead in bed syndrome in young diabetic patients in Norway. Diabet Med. 1995, 12 (9): 782-787. 10.1111/j.1464-5491.1995.tb02080.x.CrossRefPubMed
80.
Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care. 1995, 18 (11): 1415-1427.
81.
Tunbridge WM: Factors contributing to deaths of diabetics under fifty years of age. On behalf of the Medical Services Study Group and British Diabetic Association. Lancet. 1981, 2 (8246): 569-572.
82.
Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD: Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes–the EURODIAB prospective complications study. Diabetologia. 2005, 48 (2): 370-378. 10.1007/s00125-004-1628-8.CrossRefPubMed
83.
Zervou S, Wang YF, Laiho A, Gyenesei A, Kytomaki L, Hermann R, Abouna S, Epstein D, Pelengaris S, Khan M: Short-term hyperglycaemia causes non-reversible changes in arterial gene expression in a fully ‘switchable’ in vivo mouse model of diabetes. Diabetologia. 2010, 53 (12): 2676-2687. 10.1007/s00125-010-1887-5.CrossRefPubMed
84.
Chaudhuri A, Dandona P, Fonseca V: Cardiovascular benefits of exogenous insulin. J Clin Endocrinol Metab. 2012, 97 (9): 3079-3091. 10.1210/jc.2012-1112.CrossRefPubMed
85.
Forst T, Hanefeld M, Jacob S, Moeser G, Schwenk G, Pfutzner A, Haupt A: Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies. Diab Vasc Dis Res. 2013, 10 (4): 302-14. 10.1177/1479164112465442.CrossRefPubMed
86.
Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O’Neill MC, Zinman B, Viberti G: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006, 355 (23): 2427-2443. 10.1056/NEJMoa066224.CrossRefPubMed
87.
O’Keefe JH, Abuannadi M, Lavie CJ, Bell DS: Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus. Mayo Clin Proc. 2011, 86 (2): 128-138. 10.4065/mcp.2010.0434.PubMedCentralCrossRefPubMed
88.
Noh RM, Graveling AJ, Frier BM: Medically minimising the impact of hypoglycaemia in type 2 diabetes: a review. Expert Opin Pharmacother. 2011, 12 (14): 2161-2175. 10.1517/14656566.2011.589835.CrossRefPubMed
89.
Drucker DJ, Sherman SI, Bergenstal RM, Buse JB: The safety of incretin-based therapies–review of the scientific evidence. J Clin Endocrinol Metab. 2011, 96 (7): 2027-2031. 10.1210/jc.2011-0599.CrossRefPubMed
90.
Metadata
Title
Cardiac implications of hypoglycaemia in patients with diabetes – a systematic review
Authors
Markolf Hanefeld
Eva Duetting
Peter Bramlage
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2013
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-12-135

Other articles of this Issue 1/2013

Cardiovascular Diabetology 1/2013 Go to the issue

Study protocol

Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control

Original investigation

24-hour central aortic systolic pressure and 24-hour central pulse pressure are related to diabetic complications in type 1 diabetes – a cross-sectional study

Original investigation

Susceptibility to myocardial ischemia reperfusion injury at early stage of type 1 diabetes in rats

Original investigation

Effects of two weeks of metformin treatment on whole-body glycocalyx barrier properties in db/db mice

Original investigation

Plasma levels of the arterial wall protein fibulin-1 are associated with carotid-femoral pulse wave velocity: a cross-sectional study

Original investigation

Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS)
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits